|
|
2601 Fourth Avenue, Suite 500
Seattle, WA 98121 USA
phone:(206) 801-2100
fax:(206) 801-2101
|
|
| Symbol |
ONTY |
| Exchange |
Nasdaq |
| Founded |
0 |
| Employees |
|
|
|
| www.oncothyreon.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Oncology products to improve the lives and outcomes of cancer patients. |
|
| Management |
| Robert L. Kirkman, MD, President & CEO, Gary Christianson, PE, Chief Operating Officer; Diana Hausman, MD, Vice President, Clinical Development; Scott Peterson, PhD, Vice President, Research and Development; Shashi Karan, Corporate Controller |
| |
|
|
|
|
|
|
|
| Keywords |
| therapeutics, urinary tract, cervical, prostate, endometrial |
|
|
|
| Description |
|
Oncothyreon is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. We are currently developing multiple therapeutic candidates designed to target cancer in specific and effective ways. Our pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
